A Pilot Study Suggests that the G/G Genotype of Resistin Single Nucleotide Polymorphism at-420 May Be an Independent Predictor of a Reduction in Fasting Plasma Glucose and Insulin Resistance by Pioglitazone in Type 2 Diabetes
A Pilot Study Suggests that the G/G Genotype of Resistin Single Nucleotide Polymorphism at-420 May Be an Independent Predictor of a Reduction in Fasting Plasma Glucose and Insulin Resistance by Pioglitazone in Type 2 Diabetes
复制标题
DOI：
10.1507/endocrj.k08e-320
复制
发表时间：
2009-12-01
影响因子：
2
通讯作者：
Osawa, Haruhiko
中科院分区：
文献类型：
--
作者：
Makino, Hideichi;Shimizu, Ikki;Osawa, Haruhiko
本研究的目的是确定在2型糖尿病患者中，β-内酰胺酶基因启动子-420（rs 1862513）单核苷酸多态性（SNP）的G/G基因型与吡格列酮血糖控制之间的关系。在研究1中，121例2型糖尿病患者在既往药物治疗的基础上接受吡格列酮（15或30 mg/天）治疗12周。在研究2中，对63例接受吡格列酮治疗12周的患者进行了回顾性检查。在研究1中，多元回归分析显示，与C/C相比，G/G而不是C/G基因型与空腹血糖（FPG）降低和胰岛素抵抗的稳态模型评估（HOMA-IR）相关。当校正年龄、性别和BMI后，G/G基因型是FPG（P=0.020）和HOMA-IR（P=0.012）降低的独立因素。当通过调整研究、年龄、性别和BMI将研究I和2合并时，HbA 1c的降低与G/G基因型相关（β =-0.511，P=0.044）。因此，本初步研究表明，Gln SNP-420的G/G基因型可能是吡格列酮降低空腹血糖和HOMA-IR的独立预测因子。
The aim of this study was to determine the relation between the G/G genotype of a resistin gene promoter single nucleotide polymorphism (SNP) at -420 (rs1862513) and glycemic control by pioglitazone in type 2 diabetes. In Study 1, 121 type 2 diabetic patients were treated with pioglitazone (15 or 30 mg/day) for 12 weeks, in addition to previous medication. In Study 2, 63 patients who had been treated with pioglitazone for 12 weeks were examined retrospectively. In Study 1, multiple regression analysis revealed that the G/G but not C/G genotype was correlated with a reduction in fasting plasma glucose (FPG) and homeostasis model assessment of insulin resistance (HOMA-IR) compared to C/C. When adjusted for age, gender, and BMI, the G/G genotype was an independent factor for the reduction of FPG (P=0.020) and HOMA-IR (P=0.012). When studies I and 2 were combined by adjusting the studies, age, gender, and BMI, the reduction of HbA1c was correlated with the G/G genotype (beta=-0.51 1, P=0.044). Therefore, this pilot study suggests that the G/G genotype of resistin SNP -420 may be an independent predictor of the reduction of fasting plasma glucose and HOMA-IR by pioglitazone.